GREENYN Business Summary

Greenyn Biotechnology Co., Ltd. (6846.TWO) operates a diversified revenue model centered on the research, development, and manufacturing of high-performance nutraceuticals and dietary supplement ingredients. The company generates income through three primary business segments: proprietary branded ingredients (such as Insumate® bitter melon extract and Antromax® Antrodia cinnamomea), customized ODM/OEM formulation services, and the exclusive distribution of international raw materials. Greenyn has recently transitioned toward a Contract Development and Manufacturing Organization (CDMO) strategy, supported by a NT$1.7 billion AI-enabled smart factory in the Central Taiwan Science Park. Within the competitive landscape, Greenyn competes directly with major Taiwanese biotech firms such as TCI Co., Ltd. (8436.TW), Grape King Bio (1707.TW), and Synbio Tech (6605.TWO). While TCI and Grape King dominate the global ODM and domestic retail markets respectively, Greenyn maintains a specialized market fit as a niche leader in proprietary, patent-heavy ingredients, holding a 20% domestic market share in the bitter melon peptide segment. Leadership is spearheaded by Chairman Jia-Feng Wu and CEO Pang-Kuei Hsu, both of whom possess extensive pedigrees in the international health supplement and biotechnology sectors. Under their direction, the company has secured over 96 global patents and achieved U.S. FDA New Dietary Ingredient (NDI) certifications for its core products, a first for the Taiwanese industry. The executive team was further strengthened in early 2026 with the appointment of Qiuxue Zeng as Chief Financial Officer, following the company's successful 2023 listing on the Taipei Exchange. Greenyn’s founding team, which emerged from a legacy of international raw material distribution, has cultivated a research-intensive culture comprised of dozens of Ph.D. specialists in molecular medicine and food science. This technical depth has attracted a stable base of institutional investors and academic partners, positioning the firm as a key innovator in the Southeast Asian and East Asian functional food markets.